The Malaysian Health Ministry shared that they have recorded 25 cases of myocarditis in patients within 21 days after getting the C-19 shot from February to September 2021. This happened when a Malaysian group of doctors warned about the risk of side effects from the vaccine on young adults developing myocarditis and pericarditis.
From 25 cases, 14 myocarditis cases were connected to the Pfizer shot, 9 to Sinovac, and 2 to AstraZeneca.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
Yahoo Malaysia reported:
In a statement, the ministry explained that the NPRA’s reporting format would signal health professionals to any potential side effects or concerns for the safety of the vaccine, and that the government is fully committed to its continuous monitoring of the ongoing vaccination programme.
“Recently, concerns about cases of myocarditis and pericarditis related to vaccines, especially the Covid-19 mRNA vaccine for the adolescent population received a lot of public attention.
It added that the Institute of Clinical Research (ICR), National Institutes of Health (NIH) and the Health Ministry also conducted a Malaysian vaccine safety study known as Case-Based Monitoring of Adverse Events Following Covid-19 Vaccination (SAFECOVAC, NMRR-21-822-59745).
The study analysed a total of 433,674 admissions to 216 public and private hospitals from February to September 2021, and found that 25 myocarditis cases were confirmed within 21 days of receiving the Covid-19 vaccine.
Of those, 14 cases of myocarditis were reported to be related to Comirnaty, nine related to CoronaVac, and two related to Oxford-AstraZeneca.
“This SAFECOVAC study found the actual rate of myocarditis incidence for every million doses given was 0.9 for comirnaty vaccine recipients, 0.5 for CoronaVac and 0.7 for the Oxford-AstraZeneca vaccine.
“Among those under the age of 30, the actual rate of myocarditis was 0.87 per million doses given for BNT162b2 and 0.49 for CoronaVac. Whereas, for individuals aged 30 years and above, the actual rate of myocarditis is 1.0 per million doses for Comirnaty and 0.6 for CoronaVac,” said the ministry.
It said based on the results of SAFECOVAC, data from NRPA and real-world data systems, show that incidence of myocardial infarction after receiving Covid-19 vaccine are very rare as compared to getting it from a Covid-19 infection.
“Furthermore, most of the reported cases of myocarditis are mild, and limited to individuals and are immediately acted upon,” it said.
One year ago, the CDC investigated potential health issues in young adults and adolescents after the C-19 vaccination. They reported a surge in myocarditis and pericarditis cases among young adults after the second dose of the C-19 shot.
Vaccine advisors stated that there was a higher-than-expected cases number of heart issues among young adults after getting the shot. The CDC rejected this and stated that the vaccine benefits outweigh the risks.